Currently, the trial is investigating the use of convalescent plasma to treat COVID-19.

As part of the immune response, people recovering from COVID-19 can develop antibodies targeting parts of the SARS-CoV-2 virus. These antibodies are contained in the liquid part of the blood, the plasma, and can be given to patients newly infected with COVID-19 via plasma transfusion, potentially resulting in more rapid control and clearance of the virus.

More information about convalescent plasma, including how to donate if you have recovered from COVID-19, is available on the Lifeblood website.

Results will be continually analysed, so that ineffective therapies can be stopped and new therapies can be evaluated as part of the trial.